A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102)

George Perez, Rodger David MacArthur, Sharon Walmsley, John A. Baxter, Chris Mullin, James D. Neaton

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To compare the long-term clinical efficacy and toxicity of initial strategies of nelfinavir (NFV) or ritonavir (RTV) in patients with CD4+ cells below 200/mm3. Method: This was an open-label randomized multicenter trial (CPCRA, CTN). Patients were naïve to protease inhibitor use except for hard gel saquinavir. Patients who were intolerant to their assigned therapy were allowed to switch arms (later RTV-intolerant patients could switch to indinavir). The primary objective was to compare the regimens for AIDS-defining conditions and death (AIDS/death) using intent-to-treat analysis. Hazard ratios (HR) for NFV and RTV were estimated using Cox's proportional hazards models. Kaplan-Meier life table summaries were also used to compare the two groups. Results: There were 775 patients who were randomized beginning in January 1997 and followed through December 2001. At entry, mean CD4+ cell count was 58 cells/mm3 and HIV RNA level averaged 4.9 log copies/mL. After a median follow-up of 52 months, rates of AIDS/death were 12.7 and 11.0 per 100 person years for the NFV and RTV groups, respectively (HR = 1.16; 95% CI, 0.92-1.46; p = .21). Discontinuations occurred earlier in the RTV group (p = .0001). Conclusion: There are moderate differences in efficacy and large differences in tolerability between a strategy of initial NFV or RTV in patients with advanced disease. Finding the right balance between potency and tolerability remains a challenge.

Original languageEnglish (US)
Pages (from-to)7-18
Number of pages12
JournalHIV Clinical Trials
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Nelfinavir
Ritonavir
Randomized Controlled Trials
HIV
Acquired Immunodeficiency Syndrome
Saquinavir
Indinavir
Life Tables
CD4 Lymphocyte Count
Protease Inhibitors
Proportional Hazards Models
Multicenter Studies
trans-crotonin
Gels
RNA

Keywords

  • Clinical endopoints
  • Protease inhibitors
  • Tolerability

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). / Perez, George; MacArthur, Rodger David; Walmsley, Sharon; Baxter, John A.; Mullin, Chris; Neaton, James D.

In: HIV Clinical Trials, Vol. 5, No. 1, 01.01.2004, p. 7-18.

Research output: Contribution to journalArticle

Perez, George ; MacArthur, Rodger David ; Walmsley, Sharon ; Baxter, John A. ; Mullin, Chris ; Neaton, James D. / A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). In: HIV Clinical Trials. 2004 ; Vol. 5, No. 1. pp. 7-18.
@article{7a1544d3bcd54b5987c99a75cfb624b7,
title = "A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102)",
abstract = "Purpose: To compare the long-term clinical efficacy and toxicity of initial strategies of nelfinavir (NFV) or ritonavir (RTV) in patients with CD4+ cells below 200/mm3. Method: This was an open-label randomized multicenter trial (CPCRA, CTN). Patients were na{\"i}ve to protease inhibitor use except for hard gel saquinavir. Patients who were intolerant to their assigned therapy were allowed to switch arms (later RTV-intolerant patients could switch to indinavir). The primary objective was to compare the regimens for AIDS-defining conditions and death (AIDS/death) using intent-to-treat analysis. Hazard ratios (HR) for NFV and RTV were estimated using Cox's proportional hazards models. Kaplan-Meier life table summaries were also used to compare the two groups. Results: There were 775 patients who were randomized beginning in January 1997 and followed through December 2001. At entry, mean CD4+ cell count was 58 cells/mm3 and HIV RNA level averaged 4.9 log copies/mL. After a median follow-up of 52 months, rates of AIDS/death were 12.7 and 11.0 per 100 person years for the NFV and RTV groups, respectively (HR = 1.16; 95{\%} CI, 0.92-1.46; p = .21). Discontinuations occurred earlier in the RTV group (p = .0001). Conclusion: There are moderate differences in efficacy and large differences in tolerability between a strategy of initial NFV or RTV in patients with advanced disease. Finding the right balance between potency and tolerability remains a challenge.",
keywords = "Clinical endopoints, Protease inhibitors, Tolerability",
author = "George Perez and MacArthur, {Rodger David} and Sharon Walmsley and Baxter, {John A.} and Chris Mullin and Neaton, {James D.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1310/N11F-NK93-MUMR-A1VV",
language = "English (US)",
volume = "5",
pages = "7--18",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102)

AU - Perez, George

AU - MacArthur, Rodger David

AU - Walmsley, Sharon

AU - Baxter, John A.

AU - Mullin, Chris

AU - Neaton, James D.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Purpose: To compare the long-term clinical efficacy and toxicity of initial strategies of nelfinavir (NFV) or ritonavir (RTV) in patients with CD4+ cells below 200/mm3. Method: This was an open-label randomized multicenter trial (CPCRA, CTN). Patients were naïve to protease inhibitor use except for hard gel saquinavir. Patients who were intolerant to their assigned therapy were allowed to switch arms (later RTV-intolerant patients could switch to indinavir). The primary objective was to compare the regimens for AIDS-defining conditions and death (AIDS/death) using intent-to-treat analysis. Hazard ratios (HR) for NFV and RTV were estimated using Cox's proportional hazards models. Kaplan-Meier life table summaries were also used to compare the two groups. Results: There were 775 patients who were randomized beginning in January 1997 and followed through December 2001. At entry, mean CD4+ cell count was 58 cells/mm3 and HIV RNA level averaged 4.9 log copies/mL. After a median follow-up of 52 months, rates of AIDS/death were 12.7 and 11.0 per 100 person years for the NFV and RTV groups, respectively (HR = 1.16; 95% CI, 0.92-1.46; p = .21). Discontinuations occurred earlier in the RTV group (p = .0001). Conclusion: There are moderate differences in efficacy and large differences in tolerability between a strategy of initial NFV or RTV in patients with advanced disease. Finding the right balance between potency and tolerability remains a challenge.

AB - Purpose: To compare the long-term clinical efficacy and toxicity of initial strategies of nelfinavir (NFV) or ritonavir (RTV) in patients with CD4+ cells below 200/mm3. Method: This was an open-label randomized multicenter trial (CPCRA, CTN). Patients were naïve to protease inhibitor use except for hard gel saquinavir. Patients who were intolerant to their assigned therapy were allowed to switch arms (later RTV-intolerant patients could switch to indinavir). The primary objective was to compare the regimens for AIDS-defining conditions and death (AIDS/death) using intent-to-treat analysis. Hazard ratios (HR) for NFV and RTV were estimated using Cox's proportional hazards models. Kaplan-Meier life table summaries were also used to compare the two groups. Results: There were 775 patients who were randomized beginning in January 1997 and followed through December 2001. At entry, mean CD4+ cell count was 58 cells/mm3 and HIV RNA level averaged 4.9 log copies/mL. After a median follow-up of 52 months, rates of AIDS/death were 12.7 and 11.0 per 100 person years for the NFV and RTV groups, respectively (HR = 1.16; 95% CI, 0.92-1.46; p = .21). Discontinuations occurred earlier in the RTV group (p = .0001). Conclusion: There are moderate differences in efficacy and large differences in tolerability between a strategy of initial NFV or RTV in patients with advanced disease. Finding the right balance between potency and tolerability remains a challenge.

KW - Clinical endopoints

KW - Protease inhibitors

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=1642393350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642393350&partnerID=8YFLogxK

U2 - 10.1310/N11F-NK93-MUMR-A1VV

DO - 10.1310/N11F-NK93-MUMR-A1VV

M3 - Article

VL - 5

SP - 7

EP - 18

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 1

ER -